Contrasting PROCEPT BioRobotics (NASDAQ:PRCT) and SeaStar Medical (NASDAQ:ICU)

PROCEPT BioRobotics (NASDAQ:PRCT) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 19.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 4.5% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for PROCEPT BioRobotics and SeaStar Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0	0	6	0	3.00
SeaStar Medical	0	0	1	0	3.00

PROCEPT BioRobotics presently has a consensus price target of $45.60, suggesting a potential downside of 9.88%. SeaStar Medical has a consensus price target of $5.00, suggesting a potential upside of 654.60%. Given SeaStar Medical’s higher possible upside, analysts plainly believe SeaStar Medical is more favorable than PROCEPT BioRobotics.

Risk & Volatility

PROCEPT BioRobotics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.

Earnings & Valuation

This table compares PROCEPT BioRobotics and SeaStar Medical’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$136.19 million	18.93	-$105.90 million	($2.24)	-22.59
SeaStar Medical	N/A	N/A	-$23.01 million	N/A	N/A

SeaStar Medical has lower revenue, but higher earnings than PROCEPT BioRobotics.

Profitability

This table compares PROCEPT BioRobotics and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-77.75%	-46.59%	-30.63%
SeaStar Medical	N/A	N/A	-961.93%

Summary

PROCEPT BioRobotics beats SeaStar Medical on 6 of the 10 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.